Capital Group notifies 77.68M-share (4.98%) holding in AstraZeneca

Rhea-AI Filing Summary

AstraZeneca PLC received a TR-1 notification showing The Capital Group Companies, Inc. and its affiliates reported a combined holding of 77,682,857 ordinary shares, representing 4.984560% of voting rights as of 14-Aug-2025. Of that total, 14,351,342 are held as depository receipts (ISIN US0463531089), representing 0.925485% of voting rights. The filing clarifies these shares are owned by client accounts under discretionary management across Capital Group entities, not held for the parent companies' own accounts. The notification supplies the chain of controlled undertakings through which the holdings are managed and is signed by AstraZeneca's Company Secretary on 15 August 2025.

Positive

• Transparent disclosure of a combined 4.984560% stake by The Capital Group Companies on 14-Aug-2025
• Clarifies ownership is held in client discretionary accounts, not by the parent for its own account

Negative

• None.

Insights

Institutional Ownership Analyst

Capital Group reported a 4.984560% stake in AstraZeneca as of 14-Aug-2025.

The filing documents a near-5% position totaling 77,682,857 shares, including 14,351,342 depository receipts. This is a standard regulatory disclosure that informs the market about concentration of ownership by a major asset manager and clarifies the holdings sit in client discretionary accounts rather than on the parent firm's balance sheet.

This level of disclosure is material to shareholders because large institutional stakes can influence governance and voting outcomes, though the reported percentage remains below the 5% threshold that often triggers additional regulatory notices in some jurisdictions.

Corporate Governance Specialist

Near‑threshold ownership may affect voting dynamics at shareholder meetings.

The notification names the full chain of investment management entities within Capital Group, which is relevant for proxy and voting identification. Because the holdings are managed across multiple Capital Group affiliates, coordination of voting instructions could concentrate influence despite individual entities appearing smaller.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1. Holding(s) in Company

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0009895292

Issuer Name

ASTRAZENECA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City of registered office (if applicable)

Los Angeles

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

13-Aug-2025

6. Date on which Issuer notified

14-Aug-2025

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	5.009591	0.000000	5.009591	77682857
Position of previous notification (if applicable)	4.984560	0.000000	4.984560

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009895292 Common Stock		63331515		4.084106
US0463531089 Depository Receipt		14351342		0.925485
Sub Total 8.A	77682857		5.009591%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Capital Group Companies, Inc.	Capital Research and Management Company
The Capital Group Companies, Inc.	Capital International, Inc.
The Capital Group Companies, Inc.	Capital Group Private Client Services, Inc.
The Capital Group Companies, Inc.	Capital International Sarl
The Capital Group Companies, Inc.	Capital International Limited

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

12. Date of Completion

14-Aug-2025

13. Place Of Completion

Los Angeles

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 15 August 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What stake did The Capital Group report in AstraZeneca (AZN)?

The Capital Group reported owning 77,682,857 shares, equal to 4.984560% of voting rights as of 14-Aug-2025.

How many depository receipts were included in the filing for AZN?

The notification lists 14,351,342 depository receipts (ISIN US0463531089), representing 0.925485% of voting rights.

Does Capital Group hold these shares on its own balance sheet?

No. The filing states the shares are owned by client accounts under the discretionary management of Capital Group entities, not by the parent company for its own account.

When was the threshold crossing date reported?

The date on which the threshold was crossed or reached is reported as 14-Aug-2025.

Who signed the Form 6-K for AstraZeneca?

The Form 6-K is signed by Matthew Bowden, Company Secretary, dated 15 August 2025.